![]() The products are formulated by leading health professionals and food scientists with expertise in nutrition, naturopathy, and biochemistry. Vitality Superteas: Champignon’s Flagship brand, Vitality Superteas, infuses a proprietary blend of artisanal mushrooms with medicinal properties. The Company’s consumer packaged goods portfolio includes two mushroom derived products: As a result, the teams are currently conducting preclinical studies before moving on to human trials. Through a partnership with the University of Miami, they aim to develop effective psilocybin based therapeutics for the treatment of mild traumatic brain injuries and PTSD. R&D / Clinical Trials (Tassili LifeSciences)įocused on the development of therapeutics for multiple pathological and psychological diseases based on psychedelic and cannabis compounds. ![]() Additionally, their manufacturing partner has been approved by Health Canada & USFDA. Novo operates a purpose-built GMP and pharmaceutical (DIN) licensed facility in Quebec and an accredited pharmacy in Ontario. It operates as a specialty biotechnology company focused on developing delivery systems for numerous pharmaceuticals and natural molecules. Formulations & Delivery Systems (Novo Formulations)Ĭhampignon Brands acquired Novo Formulations in late March. states with a target to be operational in Q3 2020. They generated over C$1mn of revenues in their first full year of operations having administered 1,500+ ketamine treatments.Īs a result of the success, expansion is underway for 5 additional clinics across U.S. The only Health Canada approved clinic for Randomized Controlled Trial (RCT) for psilocybin. Furthermore, It has positioned itself as a vertically integrated center with expertise in R&D, clinical medicine, knowledge translation, and vocational rehabilitation. It aims to be the global leader in the R&D and application of rapid onset treatments. Leading Canadian ketamine clinic operator and psychedelic medicine IP aggregator. Psychedelics Medicine Clinic Platform (Altmed Capital Corp) ![]() Corporate StructureĬhampignon Brands operates through its 4 subsidiaries each within a different subsector in the psychedelics industry, complementing each other’s operations. In addition to trading on the Canadian Stock Exchange, They have also successfully listed in the U.S. The Company’s focus is on enhancing the health and wellness of millions of consumers through organic, non-GMO mushroom-infused formulations. ![]() It aspires to position itself to become a global force as a vertically integrated producer of artisanal medicinal mushrooms. The Company listed on the Canadian Stock Exchange in early March 2020. It plans to scale up the production of its pharmaceutical-grade psilocybin, which it can then use for clinical trials. Consequently assembling an intellectual property portfolio, clinical pipeline, and drug development platform. In Q3 2020, the Company expects to advance its research into psilocybin mushrooms through clinical trials. It targets mental health conditions including depression, post-traumatic stress disorder (PTSD), as well as substance and alcohol use disorders. The Company is pursuing the development and commercialization of rapid onset treatments capable of improving health outcomes. Champignon Brands engages in the formulation and manufacturing of novel ketamine, anaesthetics and adaptogenic delivery platforms. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |